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Background: Sterile water injections have been used as an effective intervention for the management of back pain
during labour. The objective of the current research is to determine if sterile water injections, as an intervention for
back pain in labour, will reduce the intrapartum caesarean section rate.
Methods/design:
Design: A double blind randomised placebo controlled trial
Setting: Maternity hospitals in Australia
Participants: 1866 women in labour, ≥18 years of age who have a singleton pregnancy with a fetus in a cephalic
presentation at term (between 37 + 0 and 41 + 6 weeks gestation), who assess their back pain as equal to or
greater than seven on a visual analogue scale when requesting analgesia and able to provide informed consent.
Intervention: Participants will be randomised to receive either 0.1 to 0.3 millilitres of sterile water or a normal saline
placebo via four intradermal injections into four anatomical points surrounding the Michaelis’ rhomboid over the
sacral area. Two injections will be administered over the posterior superior iliac spine (PSIS) and the remaining two
at two centimetres posterior, and one centimetre medial to the PSIS respectively.
Main outcome measure: Proportion of women who have a caesarean section in labour.
Randomisation: Permuted blocks stratified by research site.
Blinding (masking): Double-blind trial in which participants, clinicians and research staff blinded to group
assignment.
Funding: Funded by the National Health and Medical Research Council
Trial registration: Australian New Zealand Clinical Trials Registry (No ACTRN12611000221954).
Discussion: Sterile water injections, which may have a positive effect on reducing the CS rate, have been shown to
be a safe and simple analgesic suitable for most maternity settings. A procedure that could reduce intervention
rates without adversely affecting safety for mother and baby would benefit Australian families and taxpayers and
would reduce requirements for maternal operating theatre time. Results will have external validity, as the technique
may be easily applied to maternity populations outside Australia. In summary, the results of this trial will contribute
High level evidence on the impact of SWI on intrapartum CS rates and provide evidence of the analgesic effect of
SWI on back pain.
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Caesarean sections (CS) have risen annually in Australia
for over 10 years reaching 31.6% of births in 2010 [1]
(Figure 1), compared with the Organization for Eco-
nomic Co-operation and Development average of 26% in
2009 [2]. A previous CS increases the likelihood of a re-
peat caesarean section; and is associated with major ob-
stetric complications in subsequent births [3,4]; reduced
fertility [5-8], and increased risk of ectopic pregnancy
and spontaneous miscarriage [9]. Caesarean section has
been associated with an increased likelihood of admis-
sion to neonatal intensive care nurseries [10-12] and an
increased risk of neonatal mortality [13], and stillbirth in
subsequent pregnancies [14,15].
The increasing CS rate imposes significant costs on
health care systems with current Australian estimates
placing the average cost for vaginal birth between
$A3626-$A8907 compared with CS at $A8022-$A15229,
depending on complications and insurance status [15].
Interventions in labour also add to the costs. For ex-
ample, a cost analysis on the use of epidural anaesthesia
in labour demonstrated an increase in the cost of vaginal
birth by 30% and CS by 150% [16] (Figure 2). This cost
calculation did not include the increased length of in-
patient stay related to these interventions or other co-
morbidities and complications that may occur.
Lower back pain in labour – a significant problem
One in three women will experience continuous lower
back pain in labour [17]. The occipito-posterior (OP)
position of the fetus has been cited as a common con-
tributing factor [18] although there is a paucity of evi-
dence to support or refute this observation [19]. The OP
position results in deflexion of the fetal head, which then
presents a larger diameter as it enters and progresses
through the maternal pelvis, hence contributing to
obstructed labour and an increased risk of interven-
tions including epidural anaesthesia and caesarean sec-
tion [20]. Labour dystocia, characterised by very slowFigure 1 Caesarean section and instrumental births, 2001 to
2010 [1].progress in labour together with significant and
prolonged pain, further increases the risk of interven-
tion, particularly epidural anaesthetic and CS [20]. In-
deed, labour dystocia has been reported as the major
reason for a CS during labour [21]. However, due to
differences in Australian state and territory perinatal
reporting, no data are available on the actual number
performed for this reason. That said, a major Australian
metropolitan hospital reported labour dystocia as the
primary indication for 12.4% of all CSs performed in 2007
[22], with other research suggesting it was more common
in women having their first baby (primiparous), account-
ing for nearly 80% of CSs performed during labour [23].Problems related to epidural for lower back pain in
labour
Although epidural anaesthesia remains the most effect-
ive form of analgesia available to women in labour, sub-
stantial evidence describes a strong association between
epidural use and persistent OP position and subsequent
labour dystocia [20,24,25]. Epidural anaesthesia relaxes
the pelvic floor muscles, disrupting the normal mecha-
nisms of flexion and rotation of the fetal head that
would otherwise facilitate a fetus in a malposition (OP)
to self-correct [20,24,25]. There is some evidence to
suggest that epidural use may be associated with an in-
crease in instrumental birth and CS, particularly in nul-
liparous women [26]. Furthermore, epidural anaesthesia
during labour is associated with co-morbidities arising
from the need for urinary catheterisation to prevent
urinary retention [27]. Urinary catheterisation is a pri-
mary source of urinary tract infection (UTI) with one
study reporting an incidence of 30% amongst women
who were catheterised during labour [28]; postpartum
urinary retention and incontinence as a consequence
of labour-related epidural use has also been reported
[29-32].Sterile water injections as pain relief for lower back pain
in labour
Sterile water injections (SWI) into the lower back can
provide pain relief to women experiencing lower back
pain during labour although there is still uncertainty
about the effectiveness of this intervention on the im-
provement of clinical outcomes including decreased
need for epidural anaesthesia or CS [33]. A sterile water
injection, administered either intradermally or subcutane-
ously, causes osmotic and mechanical irritation resulting
in a brief (15–30 second) but significant stinging sensation
that is generally well tolerated by women. The onset of
pain relief follows almost immediately in the majority of
women and can last for up to two hours. The procedure
can be repeated a number of times [34]. The method has
Figure 2 Increase in costs as rates of intervention increase for low risk primiparous women in Australia (adapted with permission from
[16]).
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technique is easy to learn [35].
Review of previous trials of SWI in labour and effect on
CS rates
A systematic review and meta-analysis [36] undertaken
on SWI reported significant limitations. The meta-
analysis included eight trials involving 828 women and
found a CS rate of 4.6% in the sterile water injection
groups and 9.9% in the control groups (RR 0.51, 95% CI:
0.30-0.87) [36]. Women in the control groups received
normal saline placebo (six trials), acupuncture (one trial)
and standard care defined as massage, water immersion
and unrestricted mobilisation or transcutaneous electronic
nerve stimulation (one trial). The authors reviewed the
original publications of trial results and identified the fol-
lowing limitations:
 Only two reported a sample size calculation a
priori [37,38]
 The method of allocation concealment was not
described in two trials [39,40]
 It was unclear if the outcome assessment was
blinded in two trials [39,41]
 Only one trial reported complete data on pain
scores as many women gave birth prior to the final
data collection point [37]
 Two trials did not report if additional modes of
pain relief had been used following the SWI
intervention [37,38]
 Only one of the investigators reported rates of
cephalopelvic disproportion between groups [41].
The trials were all relatively small, were heterogeneous
using different techniques for administering SWIs and
assessing outcome measures, and contained a number of
potential biases. With these limitations, it is impossible
to attribute any relationship between lower CS rates inthe sterile water group to the administration of SWI.
Further, none of these trials had investigated the rela-
tionship between SWI and CS as the primary outcome;
to our knowledge, no such study has been undertaken.
The authors of the meta-analysis, noting the reduction
in CS rates and the limitations in the current literature,
recommended a large trial with CS as the primary out-
come. The National Institute of Clinical Excellence
(NICE) guidelines [33] also call for research into the ef-
fect of SWI on birth outcomes. With these issues in
mind, we have designed the trial outlined in this proto-
col following the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [42].Gaps in the research on SWI as pain relief in labour
This will be the first clinical trial statistically powered to
identify if the addition of SWI to standard maternity
care is superior to standard care alone with CS rates as
the primary outcome. Furthermore, there is limited in-
formation about analgesia, epidural anaesthesia use and
birth outcomes following sterile water injections in
labour. For example, it is not clear whether rates of in-
strumental vaginal deliveries are affected by the inter-
vention. Combined results from the two trials [40,41]
measuring this outcome show a trend towards an in-
creased instrumental birth rate in the SWI group (OR
1.91; 95% CI 0.95-3.84). Finally, none of the trials have
included a cost benefit analysis; we intend to undertake
such an analysis.Methods/design
Null hypothesis
H0: There will be no difference in the CS rate in women
experiencing lower back pain in labour when comparing
those who receive SWI with those who receive placebo.
H1: There will be at least a 30 per cent relative differ-
ence in CS rates between the treatment groups.
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Primary aim
To determine if sterile water injections, as an interven-
tion for back pain in labour, will reduce the in labour CS
rate.
Secondary aims
To determine the effects of SWI for back pain in labour
on:
 effectiveness for relieving back pain
 requirement for pain relief methods other than the
intervention
 mode of birth and complications associated with
birth (prior to hospital discharge)
 other maternal and infant outcomes in the
immediate (six weeks) postnatal period
 cost of care for women and their babies during
labour and birth, and the inpatient postnatal period
from the perspective of the health system.
Study design
A randomised, placebo controlled, double blind trial
where participants receive either SWI or injections of a
normal saline placebo. This trial will be conducted
across maternity centres in Australia. The study protocol
is registered on the Australian New Zealand Clinical
Trials Registry (No ACTRN12611000221954). Six hos-
pitals have confirmed involvement.
Participants
Women in labour with lower back pain who satisfy the




 In labour (spontaneous or induced, but not
dependent on degree of cervical dilation)
 Are ≥ (equal to or greater than) 18 years of age
 Have a term singleton pregnancy (between 37 + 0
and 41 + 6 weeks gestation)
 Have a fetus in a cephalic (head down) presentation
 Experience back pain assessed by visual analogue
scale VAS as ≥ 7 when women request analgesia for
back pain
 Are able to provide informed consent.
Exclusion criteria
Women will be excluded if they fulfil any of the follow-
ing criteria
 Multiple pregnancy Malpresentation (breech, transverse, shoulder)
 Previous CS
 Infection or inflammation at the injection sites or
complications that could cause bleeding at injection
site eg. Thrombocytopenia.
 Private insurance status
Private insurance status refers to women who utilise
their health insurance to enable intrapartum care to be
provided by the obstetrician of their choice. Only one
site routinely offers women this model of care, whilst all
sites offer obstetric care provided by publically a funded
health system. Furthermore the use of private health in-
surance for obstetric care has also been associated with
higher rates of CS than for those women receiving ob-
stetric care through the public health system [43,44].
Recruitment and consent process
This trial requires the recruitment and consent of
women in labour. Pain associated with labour, together
with the possible use of pharmaceutical analgesic agents
including narcotics, may impact on a woman’s capacity
to understand new information and make informed de-
cisions, including whether to participate in research. By
way of acknowledging the Australian National Statement
on Ethical Conduct in Human Research [45] which rec-
ognises pregnant women as a potentially vulnerable
group, consent processes in this study will reflect Na-
tional Health and Medical Research Council (NHMRC)
guidelines 4.1.1 to 4.1.10 [45]. That said, recent evidence
suggests that women in labour are able to consent to
participation in research, particularly when a staged
approach is used [46]. This may be achieved by provid-
ing information well in advance of recruitment, for ex-
ample during the antenatal period, which allows
prospective participants time to consider it and discuss
their potential involvement in the research with family
members and significant others, including health care
providers [46,47].
Recruitment will be undertaken at five metropolitan
and regional maternity units in Queensland (QLD) and
one metropolitan unit in New South Wales (NSW)).
Hospital-based antenatal care providers will offer all eli-
gible women a participant information and consent form
(PICF) and discuss the purpose and design of the study
during the antenatal period. As most participating hospi-
tals, require women to return to the antenatal clinic in the
third trimester of pregnancy (between 32 and 36 weeks),
this provides an ideal opportunity to disseminate informa-
tion, briefly discuss the study, and answer any immediate
queries arising. At sites that do not employ this method of
contact, the PICF will be provided at the time of booking
into the hospital and distributed through the antenatal
education classes. Consent will not be sought in the
Figure 3 Injection sites for administration – control
and intervention.
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at each site are included on the PICF to enable women to
seek more information if desired.
When women are in labour, they typically present to
the Birth Suite of their respective hospital. Women will
not be asked to consent to participation until such time
as they have been fully assessed for eligibility against the
inclusion and exclusion criteria. Although the majority
of women will have received information regarding the
trial during pregnancy, on admission to Birth Suite, staff
will remind them of the trial and offer interested, and
potentially eligible, women another copy of the PICF,
and answer any outstanding questions.
Consent processes will be undertaken by the clinical
trial co-ordinator at each site, or in their absence, a mid-
wife who is not providing direct care to the woman. In
our previous trial [48], women had no objections to
consenting in labour, and when they were requesting an-
algesia for back pain. However as consent for clinical
care differs from that required for research, if the person
seeking consent considers that labour is too far ad-
vanced, or for any other reason staff consider women to
be incapable of considering all available choices in clin-
ical care, and of making an informed and voluntary con-
sent, participation in the trial will not be sought.
Once the consent process has been completed, the
woman will be randomised.
Sample size
The meta-analysis of SWI use reported the overall rate
of ‘in labour’ CS as 9.9% in the control group and 4.6%
in the intervention (SWI) group [36] – i.e. a greater than
50% reduction in the CS rate in the SWI group. How-
ever, the review included trials where women receiving
SWI were compared with women receiving either a pla-
cebo or other interventions (eg. acupuncture), and in-
cluded trials that were conducted over two decades ago
(1990 to 2008): a significant increase in CS rates (% in
1991 [49] to 31.5% in 2009 [50]) has been recorded in
the intervening period.
More recently, at a metropolitan hospital in QLD, rou-
tine birth outcome data were collected on all women in
labour who received SWI during 2010 (n = 427). The CS
rate for women in the SWI group was 12.5%. The ‘in
labour’ CS rate for women receiving standard care dur-
ing the same period was 17.5%. This represents a differ-
ence of 30% which we suggest may conservatively reflect
the contemporary clinical trend in CS rates. To demon-
strate a similar reduction (17.5% to 12.5%), our study re-
quires 839 women in each group (80% power, type I
error 0.05). The attrition rate in our previous trial was
13% [48], however this was largely due to women giving
birth prior to the measurement of the primary outcome
(pain at 30 mins) and the use of nitrous oxide inhalationprior to randomisation. Neither of these are exclusion
factors in this trial, therefore we expect attrition to be
minimal and propose an attrition rate of 10%. The total
sample size required is therefore 1886 women. As some
sites have higher annual birth rates than other sites, the
recruitment allocation anticipated for each site will be
proportional.
Definition of intervention, control and standard care
Intervention
Participants in the intervention group will receive injec-
tions of 0.1–0.3 millilitres of sterile water for injection
into four anatomical points surrounding the Michaelis
rhomboid over the sacral area, two over the posterior
superior iliac spines (PSIS) and the remaining two at
two centimetres posterior, and one centimetre medial, to
the PSIS respectively (Figure 3). This is a standard ap-
proach described in the majority of previous trials and
has been demonstrated to be the most effective technique
[34,48]. The actual volume injected, which may vary
slightly depending on minor differences in tissue depth, is
determined by a visual assessment of the resulting ‘bleb’
or blister. Minor discrepancies or changes to the anatom-
ical position, depth or alignment of the four injections
have not been shown to impact on any analgesic effect
[51]. Injections will be given using 23 gauge needles or
similar depending on actual equipment available at each
site. One repeat injection will be provided for women who
request them. Education sessions will be provided at all
sites by the project manager, who has developed a dedi-
cated ‘train the trainer’ course. All clinicians administering
SWI will to be credentialed in this technique.
Control
Participants in the control group will receive 0.1 – 0.3
millilitres of normal saline 0.9% for injection into the
same four anatomical points surrounding the Michaelis
rhomboid as previously described. Repeat injections will
also be provided as required (Figure 3).
Care during labour
All women will receive care throughout labour and birth
as required according to routine Australian clinical
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Preliminary planning using data from perinatal databases
at each site reveals that non-pharmacological and
pharmacological analgesic options are similar; and have
been incorporated into our definition of ‘standard care’.
Non-pharmacological options include water immersion,
aromatherapy, massage, and hot showers. Pharmaco-
logical options include Nitrous Oxide inhalation, nar-
cotics (pethidine and morphine) and epidural or spinal
anaesthesia. Intervention rates (e.g., epidural and CS) are
similar across sites. At a number of current and planned
research sites SWI is not available as standard care
(demonstrating the importance of research in this area).
Sterile water injections are available at site one, two and
four, and women requesting SWI at these sites will not
be entered into the trial.
Randomisation and blinding
Blinded (plain label) ampoules of sterile water (interven-
tion) and normal saline (placebo) for injection will be
prepared by the Mater Health Service Pharmacy for all
sites, and labelled according to a randomisation schedule
prepared by the Mater Medical Research Institute. The
ampoules will be delivered to each of the sites and
stored in a locked container. The randomisation sched-
ule will use permuted blocks and will be stratified by re-
search site. In our previous trial about 10% of
participants requested a repeat dose, to provide for this
with minimal crossover between groups (e.g., women
randomised to normal saline receiving sterile water as a
repeat dose) each allocation packet will include two am-
poules of the allocated treatment. Following consent,
two midwives (other than the midwife assigned to pro-
vide the woman’s care in labour, or ‘primary midwife’)
will obtain the next ampoule in numbered order and ad-
minister the injections. As this is a double blind trial,
the administering midwives will be unaware of the arm
to which the participant has been allocated. The am-
poule number will be recorded in a research log and on
the data collection forms. As the injection of normal
saline does not result in the same degree of adminis-
tration pain as sterile water, both interventions will
be administered by midwives other than the primary
midwife, who will be absent from the room through-
out. This will prevent the primary midwife from
observing the woman’s reaction to the administration
which reduces the likelihood of assumptions being
made about the arm of the trial into which the
woman has been randomised.
Outcome measures
Primary outcome
 Proportion of women who have a CS in labourSecondary outcomes
 Proportion of women undergoing induction and/or
augmentation of labour
 Proportion of women receiving epidural anaesthesia
 Proportion of women having instrumental vaginal
births
 Primary indication for CS
 Visual analogue scale of back pain prior to SWI
 Visual analogue scale of back pain following SWI
(10, 45 minutes)
 Length of 1st stage and 2nd stage of labour
 Results of most recent vaginal assessment prior to
randomisation
 Position of fetal occiput in relation to the maternal
pelvis prior to randomisation and how this was
determined
 Proportion of women breastfeeding at discharge
 Proportion of neonates admitted to the neonatal
intensive care unit
 Cost of care from admission in labour until
discharge of mother and baby from hospital from
the perspective of the health system.
 Experience of satisfaction, relaxation, social support,
negative side effects and memory of pain.Data management
Data sources
Obstetric and neonatal outcome data will be obtained
from either the onsite obstetric database where available
or the Perinatal Data Collection unit in each state.
The VAS will be used to measure perceptions of pain.
The VAS is an ungraded 100 mm long horizontal
straight line with the endpoints “no pain” to the left (0)
and “worst pain imaginable” to the right (100) [52]. To
record a VAS, a participant marks a point on the line
that matches the amount of pain experienced. The point
is then quantified by measuring the distance in millimetres
between “No Pain” and the point marked by the woman
against a 0-10 cm gauge. The VAS has been shown to be
sensitive to pain intensity and most individuals have no
difficulties with its use [53].
Data for the cost effectiveness analysis (CEA) will be
obtained from the perinatal database and will include
data on interventions during labour and the postnatal
period, length of stay, admission to neonatal nursery,
mode of birth, and other analgesia requirements. In
addition, data on staffing required during labour (num-
ber of midwives and time required from each midwife
for care provided during labour) will be collected. Data
on hospital costs will be obtained through the health
service managers. These will include staffing, equipment
and consumables for each woman and baby.
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Identified data collection forms will be kept in locked
storage on each site prior to secure transfer to the Pro-
ject Team. Upon receipt, data will be entered onto a
specifically designed password protected database by
designated research staff, all individual data will be de-
identified through allocation of a unique study code.
Data entry and storage, both paper and electronic will
be managed and maintained as specified in the Human
Research Ethics Committee (HREC) approvals for a
period of not less than 15 years.Data analysis
Statistical methods
All women who underwent randomisation will be
analysed in their allocated treatment groups (ie. intention
to treat). Relative risks with 95% confidence intervals for
the primary outcome will be calculated. Secondary out-
come measures of categorical data will be analysed with
chi-squared tests and continuous data will be analysed
with t-tests for normally distributed data and Mann–
Whitney U test for parametric data. Regression will be
used if necessary to adjust for any other confounding vari-
ables. All study outcomes will be analysed using a two-
sided P value of < 0.05 to indicate statistical significance.
The study is only powered to report the primary outcome
and for secondary outcomes confidence intervals (CI) will
be included as a measure of the effect size. Differences in
pre and post VAS scores will be reported in the format
recommended by the recent Cochrane Review [54].Economic analysis
The cost-consequences analysis will be undertaken from
the perspective of the hospitals to determine if the sterile
water injection is a cost-effective measure to reduce back
pain in labour compared to the normal saline injection
[55]. Direct costs will be measured for mother and baby
from consent to participate in the study until discharge
from hospital and mothers and babies re-admission to
the same hospital within 28 days of births. Information
about resource use and costs will be collected at each
site. The study will conduct a bottom-up costing for the
intervention and pain-relief methods at each site. The
costs included in the study are: costs for the intervention
(1 ampoule of sterile water or normal saline (10 ml),
2 x 1 ml syringes, 2x1 25 gauge needles, 2 alcohol
prep swabs and the midwives’ time to administer the
intervention, costs of care in labour, birth, postnatal
and neonatal admission, and re-admission costs
within 28 days of births. Costs will be allocated to the
relevant resource items using appropriate values. For
example, staff time will be costed using hourly award
rates plus on-costs; and the costs of care in labour,birth and postnatal in hospitals will be costed using
appropriate Diagnosis Related Groups.
Study duration
Study enrolment will commence after HREC approval is
obtained at each site. Enrolment is expected to continue
for 18–24 months across all sites; recruitment rates have
been conservatively estimated based on our previous
trial. The study duration will be three years and the pri-
mary endpoint will be time of birth.
Trial governance
To assist with trial governance Collaborative Trial Agree-
ments (CTA) will be established between each of the trial
sites and the sponsor (ACU). Site investigators that are
signatories to the agreements will be required to provide
reports on site activities at the quarterly Research Team
meetings and liaise with the Project Manager on an on-
going basis. Case report data on each participant will be
collected directly from state and/or hospital databases, de-
identified and stored on a password protected database.
The case report data will be managed by the Project
Leader, or designated research team member and made
available to Principal Investigator.
Staff training
Administration of SWI
Sterile water injections are currently in use at some sites.
Each of the sites in which SWI is already utilised have
developed protocols, clinical guidelines for the use of
SWI and training and competency documents based on
information provided previously by the members of the
research team. Therefore there is already a standard ap-
proach to SWI at these sites. A number of the sites do
not currently use SWI and will be provided with training
materials by the researchers, forms for assessing compe-
tency is contained within the trial documentation for
use by these sites. The training will consist of workshops
provided by the researchers and access to an online edu-
cation resource. This resource will be available to all
staff at each of the sites and can be accessed via any
internet connected computer. This process will ensure a
consistent approach to the administration of the inter-
ventions. The procedure is more commonly undertaken
by midwives, however particularly in regional sites, other
clinicians for whom the administration of injections is a
normal part of their scope of practice, may also receive
training in SWI administration.
Study processes
The researchers will hold regular in-service sessions at
each site to provide staff with information about the study
processes and procedures, specifically, participant recruit-
ment, consent and data collection. The in-service sessions
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sure trial integrity across sites. As consent will be under-
taken during labour, to ensure similar information is
provided to all women during the consent process, a
guideline script will be provided to staff for use when
discussing the trial.
Ethical aspects
Human Research Ethics Committee (HREC) approval for
all current sites has been provided by the Royal Brisbane
and Women’s Hospital HREC, according to the single site
HREC approval for multicentre clinical trials guidelines.
Research governance approval has been provided by the
Research Governance Office at each site.
Potential risks
No adverse events, allergic or systemic reactions to the
procedure have been reported in the literature other
than the brief stinging sensation immediately following
administration [51].
Data safety and monitoring
A multidisciplinary (statistician, clinical expert and re-
search expert) Data and Safety Monitoring Committee
(DSMC) will review all adverse events, which will also
be reported by site staff to the participating institution’s
Human Research Ethics Committee. In the case of com-
plications or adverse events, participants will continue to
receive routine care and have access to the research staff
named in this protocol. The DSMC, which will be
blinded to treatment allocation, will undertake interim
analysis for safety and/or efficacy once 50% of the
women have enrolled. The interim analysis will assess
for any untoward outcomes and ensure sample size and
power calculations are appropriate based on the ob-
served difference between groups for the primary
outcome.
Interruption of the study
The CIs may terminate this study prematurely, either in
its entirety or at individual study centres, for reasonable
causes (e.g. unsatisfactory enrolment with respect to
quantity or quality, inaccurate or incomplete data collec-
tion, falsification of records, failure to adhere to proto-
col). In such a case, a written notice of the intended
termination will be sent to the site investigator. The site
investigator may also terminate the study prematurely at
his/her study centre for reasonable cause, after providing
a written notice to the CIs at least 4 weeks prior to the
intended date of termination.
Discussion
In 2008 over 80,000 women in Australia underwent CS
[56]. The rising CS rate, and associated, social, medicaland economic impacts, has been recognised by govern-
ments and policy makers as a key priority area calls for
future research to specifically target CS rates [15]. In-
deed, the New South Wales Department of Health [57]
has set a State-wide target for health services to reduce
CS rates to 20% by 2015, through employing strategies
such as non-pharmacological analgesia for women in
labour. Sterile water injections, which may have a posi-
tive effect on reducing the CS rate, have been shown to
be a safe and simple analgesic suitable for most mater-
nity settings. However, results of a recent cross sectional
study of SWI use amongst Australian midwives indicated
that it was not routinely available as an analgesic choice
for labouring women in most maternity units [58], lack
of robust evidence in this area may help to explain why
the technique is not more widely used. A procedure that
could reduce intervention rates without adversely affect-
ing safety for mother and baby would benefit Australian
families and taxpayers and would reduce requirements
for maternal operating theatre time. Results will have ex-
ternal validity, as the technique may be easily applied to
maternity populations outside Australia. In summary,
the results of this trial will contribute:
1. High level evidence on the impact of SWI on
intrapartum CS rates
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